Literature DB >> 25444316

Mesohepatectomy for centrally located large hepatocellular carcinoma: Indications, techniques, and outcomes.

Lian-Yue Yang1, Rui-Min Chang2, Wan-Yee Lau3, Di-Peng Ou4, Wei Wu4, Zhi-Jun Zeng4.   

Abstract

BACKGROUND: Whether mesohepatectomy should be performed for large hepatocellular carcinoma (HCC) located in the central part of the liver is controversial, and the safety and long-term survival after this operation remain to be investigated.
METHODS: Between January 2002 and December 2012, 696 patients with HCC located in the central part of the liver who received liver resection in our hospital were included in this study. These patients were divided into three groups: 158 patients with large HCC (tumor size >5.0 cm) and 192 patients with small HCC (tumor size ≤ 5.0 cm) who received mesohepatectomy were classified as the mesohepatectomy for large HCC (MHG-L) group and the mesohepatectomy for small HCC (MHG-S) groups, respectively, and 346 patients with large HCC who received hemihepatectomy or less were classified as the non-mesohepatectomy for large HCC (NMHG-L) group. The operative indications, techniques, and outcomes of the three groups were analyzed retrospectively.
RESULTS: There were no substantial differences among the three groups in in-hospital mortality or postoperative complication rates. The overall survival and disease-free survival were not different between the MHG-L group and the NMHG-L group or between the MHG-L group and the MHG-S group. Univariable and multivariable analyses of the MHG-L mesohepatectomy group indicated that cirrhosis, tumor number, and vascular invasion were independent risk factors of poor long-term survival of mesohepatectomy. In the MHG-L and NMHG-L groups, solitary large hepatocellular carcinoma had better long-term survival than nodular large hepatocellular carcinoma.
CONCLUSION: Mesohepatectomy is safe and efficacious for BCLC B/C patients who have centrally located large HCC, especially for solitary tumors, with good survival outcomes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25444316     DOI: 10.1016/j.surg.2014.05.012

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

1.  Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Ying He; Zhousan Zheng; Yi Xu; Huiwen Weng; Ying Gao; Kai Qin; Jian Rong; Cui Chen; Miao Yun; Jiaxing Zhang; Sheng Ye
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling.

Authors:  Rui-Min Chang; Jiang-Feng Xu; Feng Fang; Hao Yang; Lian-Yue Yang
Journal:  Tumour Biol       Date:  2016-02-10

3.  Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence.

Authors:  Weiqi Rong; Weibo Yu; Liming Wang; Fan Wu; Kai Zhang; Bo Chen; Chengli Miao; Liguo Liu; Songlin An; Changcheng Tao; Weihu Wang; Jianxiong Wu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

4.  Anatomical sites (Takasaki's segmentation) predicts the recurrence-free survival of hepatocellular carcinoma.

Authors:  Wei Qin; Li Wang; Beiyuan Hu; Huan Tian; Cuicui Xiao; Huanxian Luo; Yang Yang
Journal:  BMC Surg       Date:  2021-06-03       Impact factor: 2.102

5.  A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (>5 cm) hepatocellular carcinoma.

Authors:  Hong-Chuan Zhao; Ruo-Lin Wu; Fu-Bao Liu; Yi-Jun Zhao; Guo-Bin Wang; Zhi-Gong Zhang; Fan Huang; Kun Xie; Xiao-Ping Geng
Journal:  HPB (Oxford)       Date:  2016-09-14       Impact factor: 3.647

6.  High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma.

Authors:  Yi Xu; Jian Rong; Shiyu Duan; Cui Chen; Yin Li; Baogang Peng; Bin Yi; Zhousan Zheng; Ying Gao; Kebing Wang; Miao Yun; Huiwen Weng; Jiaxing Zhang; Sheng Ye
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

7.  Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.

Authors:  Xiong Lei; Yun-Feng Li; Guo-Dong Chen; Di-Peng Ou; Xiao-Xin Qiu; Chao-Hui Zuo; Lian-Yue Yang
Journal:  Oncotarget       Date:  2015-12-01

8.  JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.

Authors:  Xiong Lei; Jiang-Feng Xu; Rui-Min Chang; Feng Fang; Chao-Hui Zuo; Lian-Yue Yang
Journal:  Oncotarget       Date:  2016-06-28

9.  Sorcin Predicts Poor Prognosis and Promotes Metastasis by Facilitating Epithelial-mesenchymal Transition in Hepatocellular Carcinoma.

Authors:  Xiong Lei; Yahang Liang; Jian Chen; Shuai Xiao; Jian Lei; Jianfeng Li; Jinzhong Duanmu; Qunguang Jiang; Dongning Liu; Cheng Tang; Taiyuan Li
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

10.  Expression of Wnt3a in hepatocellular carcinoma and its effects on cell cycle and metastasis.

Authors:  Caijie Lu; Yifeng He; Juan Duan; Yongguang Yang; Chunqiang Zhong; Jian Zhang; Weiguo Liao; Xiaojie Huang; Runzhi Zhu; Mingyi Li
Journal:  Int J Oncol       Date:  2017-09-01       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.